HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Apolipoprotein(a) acts as a chemorepellent to human vascular smooth muscle cells via integrin αVβ3 and RhoA/ROCK-mediated mechanisms.

Abstract
Lipoprotein(a) (Lp(a)) is an independent risk factor for the development of cardiovascular disease. Vascular smooth muscle cell (SMC) motility and plasticity, functions that are influenced by environmental cues, are vital to adaptation and remodelling in vascular physiology and pathophysiology. Lp(a) is reportedly damaging to SMC function via unknown molecular mechanisms. Apolipoprotein(a) (apo(a)), a unique glycoprotein moiety of Lp(a), has been demonstrated as its active component. The aims of this study were to determine functional effects of recombinant apo(a) on human vascular SMC motility and explore the underlying mechanism(s). Exposure of SMC to apo(a) in migration assays induced a potent, concentration-dependent chemorepulsion that was RhoA and integrin αVβ3-dependent, but transforming growth factor β-independent. SMC manipulation through RhoA gene silencing, Rho kinase inhibition, statin pre-treatment, αVβ3 neutralising antibody and tyrosine kinase inhibition all markedly inhibited apo(a)-mediated SMC migration. Our data reveal unique and potent activities of apo(a) that may negatively influence SMC remodelling in cardiovascular disease. Circulating levels of Lp(a) are resistant to lipid-lowering strategies and hence a greater understanding of the mechanisms underlying its functional effects on SMC may provide alternative therapeutic targets.
AuthorsKirsten Riches, Larissa Franklin, Azhar Maqbool, Michelle Peckham, Matthew Adams, Jacquelyn Bond, Philip Warburton, Nicole T Feric, Marlys L Koschinsky, David J O'Regan, Stephen G Ball, Neil A Turner, Karen E Porter
JournalThe international journal of biochemistry & cell biology (Int J Biochem Cell Biol) Vol. 45 Issue 8 Pg. 1776-83 (Aug 2013) ISSN: 1878-5875 [Electronic] Netherlands
PMID23726972 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.
Chemical References
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Integrin alphaVbeta3
  • Transforming Growth Factor beta
  • Protein-Tyrosine Kinases
  • rho-Associated Kinases
  • Extracellular Signal-Regulated MAP Kinases
  • Apoprotein(a)
  • rhoA GTP-Binding Protein
Topics
  • Apoprotein(a) (pharmacology)
  • Cell Shape (drug effects)
  • Chemotaxis (drug effects)
  • Enzyme Activation (drug effects)
  • Extracellular Signal-Regulated MAP Kinases (metabolism)
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors (pharmacology)
  • Integrin alphaVbeta3 (metabolism)
  • MAP Kinase Signaling System (drug effects)
  • Muscle, Smooth, Vascular (cytology)
  • Myocytes, Smooth Muscle (cytology, drug effects, enzymology)
  • Protein-Tyrosine Kinases (metabolism)
  • Transforming Growth Factor beta (metabolism)
  • rho-Associated Kinases (metabolism)
  • rhoA GTP-Binding Protein (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: